Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Other Non-Current Assets (2019 - 2025)

Burning Rock Biotech has reported Other Non-Current Assets over the past 7 years, most recently at $53295.2 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 3.08% year-over-year to $53295.2; the TTM value through Dec 2025 reached $53295.2, down 3.08%, while the annual FY2025 figure was $54000.0, 95.03% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $53295.2 at Burning Rock Biotech, down from $912000.0 in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $7.1 million in Q4 2021 and troughed at $53295.2 in Q4 2025.
  • A 5-year average of $2.3 million and a median of $1.6 million in 2023 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: skyrocketed 191.43% in 2021 and later crashed 92.22% in 2024.
  • Year by year, Other Non-Current Assets stood at $7.1 million in 2021, then plummeted by 58.39% to $2.9 million in 2022, then plummeted by 75.94% to $706659.1 in 2023, then crashed by 92.22% to $54990.2 in 2024, then decreased by 3.08% to $53295.2 in 2025.
  • Business Quant data shows Other Non-Current Assets for BNR at $53295.2 in Q4 2025, $912000.0 in Q3 2025, and $926000.0 in Q2 2025.